Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
72.14
+1.91 (2.72%)
At close: May 12, 2025, 4:00 PM
73.00
+0.86 (1.19%)
After-hours: May 12, 2025, 7:42 PM EDT
Corcept Therapeutics Revenue
Corcept Therapeutics had revenue of $157.21M in the quarter ending March 31, 2025, with 7.09% growth. This brings the company's revenue in the last twelve months to $685.45M, up 30.93% year-over-year. In the year 2024, Corcept Therapeutics had annual revenue of $675.04M with 39.94% growth.
Revenue (ttm)
$685.45M
Revenue Growth
+30.93%
P/S Ratio
10.61
Revenue / Employee
$1,370,892
Employees
500
Market Cap
7.65B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 675.04M | 192.67M | 39.94% |
Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CORT News
- 6 days ago - Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Business Wire
- 14 days ago - CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL - Business Wire
- 19 days ago - CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 - Business Wire
- 20 days ago - Corcept: Maintaining Strong Buy Even After 4Q Revenue And Earnings Miss - Seeking Alpha
- 21 days ago - Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes - Business Wire
- 27 days ago - It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder - Seeking Alpha
- 5 weeks ago - Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer - Business Wire